Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease
Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 5, pp. 593-603
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis
Virginia Solitano, Antonio Facciorusso, Dermot McGovern, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 12, pp. 3019-3029.e5
Open Access | Times Cited: 24
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
Esteban Fuentes-Valenzuela, Francisco Javier García‐Alonso, Carlos Maroto-Martín, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1586-1593
Closed Access | Times Cited: 20
Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Leticia Rodríguez-Alcolado, Elena Grueso-Navarro, Ángel Arias, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 7, pp. 1034-1052
Closed Access | Times Cited: 6
Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease
Abigail Samuels, Kei Irie, Tomoyuki Mizuno, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 2
Open Access
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
Sara Salvador‐Martín, Paula Zapata-Cobo, Marta Velasco Rodríguez‐Belvís, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1797-1797
Open Access | Times Cited: 12
Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
Tina Deyhim, Adam S. Cheifetz, Konstantinos Papamichael
Journal of Clinical Medicine (2023) Vol. 12, Iss. 22, pp. 7132-7132
Open Access | Times Cited: 12
Precision medicine in inflammatory bowel disease
Zhen Zeng, Mingshan Jiang, Xi Li, et al.
Precision Clinical Medicine (2023) Vol. 6, Iss. 4
Open Access | Times Cited: 11
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance
Ruben J. Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 5, pp. 524-539
Open Access | Times Cited: 16
Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease
Johannes Stallhofer, Jan Guse, Miriam Kesselmeier, et al.
International Journal of Colorectal Disease (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 9
Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn’s Disease Therapeutic Outcomes Assessed Clinically and Endoscopically
Emily K. Wright, María Chaparro, Paolo Gionchetti, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 2, pp. 212-222
Closed Access | Times Cited: 7
Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease
Abigail Samuels, Kaitlin G. Whaley, Phillip Minar
Current Gastroenterology Reports (2023) Vol. 25, Iss. 11, pp. 323-332
Open Access | Times Cited: 7
Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy
Elke O. Kreps, S. J. Epps, Alejandra Consejo, et al.
Eye (2023) Vol. 38, Iss. 5, pp. 871-876
Open Access | Times Cited: 6
Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics
Ruben J. Colman, S Vuijk, Ron A. A. Mathôt, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. 10, pp. 1678-1685
Closed Access | Times Cited: 1
A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease
Mathilde Barrau, Manon Duprat, Pauline Veyrard, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 4, pp. 633-643
Closed Access | Times Cited: 8
From Dose to Exposure: Shifting the Paradigm of Pediatric Clinical Pharmacology Research and Education
Ronaldo Morales, Victor Amajor, Kelli Paice, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 515-517
Closed Access | Times Cited: 1
Challenges in IBD Research 2024: Pragmatic Clinical Research
Jessica R. Allegretti, Liliana Bordeianou, Oriana M. Damas, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S55-S66
Open Access | Times Cited: 1
Prognostication in inflammatory bowel disease
Elizabeth Spencer, Manasi Agrawal, Tine Jess
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 7
The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control During Treatment of Pediatric Crohn’s Disease with Infliximab
Marla C. Dubinsky, Shervin Rabizadeh, John C Pannetta, et al.
(2023)
Open Access | Times Cited: 3
Biomarkers That Predict Crohn’s Disease Outcomes
Pablo A. Olivera, Mark S. Silverberg
Journal of the Canadian Association of Gastroenterology (2023) Vol. 7, Iss. 1, pp. 59-67
Open Access | Times Cited: 2
Effectiveness of strategies to suppress antibodies to infliximab in pediatric inflammatory bowel disease
Jasmijn Z. Jagt, K. Holleman, Marc A. Benninga, et al.
Journal of Pediatric Gastroenterology and Nutrition (2023) Vol. 78, Iss. 1, pp. 57-67
Open Access | Times Cited: 2
Letter: immunogenicity is not the root cause for loss of response to anti‐TNF agents in patients with IBD in TDM era
Dahham Alsoud, Bram Verstockt, Séverine Vermeire
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 7, pp. 885-886
Closed Access | Times Cited: 4
The Role of Therapeutic Drug Monitoring in Children
Alexander Nasr, Phillip Minar
Gastroenterology Clinics of North America (2023) Vol. 52, Iss. 3, pp. 549-563
Open Access | Times Cited: 2
The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
Marla C. Dubinsky, Shervin Rabizadeh, John C. Panetta, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2408-2408
Open Access | Times Cited: 2
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis
Yang Hu, Zaiwei Song, Yuan Gao, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 10, pp. 935-948
Open Access
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn’s Disease
Jeremy Adler, Joseph A. Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology (2024)
Closed Access
Page 1 - Next Page

Scroll to top